Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Outstanding research again, Changes!
I know sarcoidosis patients focus groups have been clamoring to recruit and resume the trials for years now. Should be a roaring success for enrolment.
BTW what is not included in the cool clinical language on how "the disease presents itself" is that if you saw a sarcoidosis patient coming your way on a sidewalk you most likely would cross to the other side of the street as many of them are full of lesions and pockmarks almost as if they had the plague...
Vanilla, why don't you use he extraordinary amount of free time you seem to have to contact Dr.Javitt by e-mail (preferrably with your real name and adress) and share your concerns in a civil manner .
I am hopeful he will respond if you ask nicely and thus you could assuage both your own as well as many other's worries.
It really does not change anything for any good to post your outrage here foaming at the mouth.
However with your persistence and some kind of polite language you may very well succeed in eliciting a response both by Dr. Javitt (who I suspect is accomodating) and maybe even from the german PR office of RLF
Sarcoidosis is a crippling disease!
I recall you posted on it before including the staggering numbers in the world wide market for such a therapeuticum!
This trial is conducted at the University Klinikum of Freiburg which brought Aviptadil back on the map with their publication in the New England Journal of Medicine. They first tried to start this trial 3 years ago but had to abandon it on both safety concerns as well as lack of funding due to Covid 19.. how ironic..
Since ADVITA was founded by the same department before they sold it to RELIEF I wonder wether they use that income to fund the trial or wether RLF is funding it?
Buyside institutional investors regular protocol is to short any stock they buy in a private placement!
However they do that to make money twice as most all of these placements also include warrants (take GEM e.g.).
So they make money on the short sale covering with their own shares at the exercise price with a nice yield of 5 to 15 % which BTW is a lot annualized when this is done on a professional level as most of these private placements are purely transactional and short term
They are routinely done on an ongoing schedule much like a bank loan WITHOUT a view to hold on to the shares for years to come but for a quick return and freeing up the invested money in a timely fashion... and IF (!?!) the share price rises in a meaningful way they still have warrants thrown into the deal for free which they can exercise at a low conversion rate which will do
just fine for additional revenue.
However I do not see a warrant bundle added on to the deal here so it will probably play out as a bet on a binary event... except you and I as well as most of our members on this board will hurt more than the Tute if it goes bad..
P.S.:
The SIX-Exchange allows for shorting RLF in case you did not know and the PR spells out that the investment is in the SIX quoted swiss shares...
IF(!?!) the institutional investor knew it would be front running and totally illegal and Ram could face prison time ..
Of course there are ways around it but not with a publicly announced deal.
Buying into a company for 10m SFr worth of shares just days before a binary event for a substantial buyside investor is pretty much the same as if you go to Vegas an dput 100$ on Red at the roulette table..
Your so unexcited about the outcome that you likely walk off to get a drink whilst the wheel is spinning to come back later to check on the result..
It is a report from awp-robot a pay for service provided by AWP-Finanznachrichten
Thx for bringing this out! Was about to point to that possibility
Here are the real numbers of share sales by insiders on the SIX exchange
(BTW [b]:"achat" means BUY and[i]"vente")) means SELL)
Fun Fact:
His Highness the Princ eof Liechtenstein appears to at least have been a major stake holder...
So if you want to freak out, do your DD first and PLEASE :
STOP USING ALL CAPS!
Thank you in advance!
Relief Therapeutics détient 8,781% en positions d'achat
(revoici avec titre traduit)
Stans (awp) - Relief a annoncé le changement suivant au sein de son actionnariat, conformément au règlement de la Bourse suisse (date de publication: 09.03.2021):
actionnaire participation naissance de participation
actuelle l'obligation antérieure
Relief Therapeutics
- positions d'achat: 3,85% 03.03.2021 -
- positions de vente 8,781 03.03.2021 7,372%
motifs: achat, augmentation de capital
annonces précédentes:
Christopher Brown, New York, über 46,22% 22.01.2021
GEM Global Yield LLC SCS, Luxemb.
Yves Sagot, FR 2,63% 22.01.2021
Relief Therapeutics
- positions de vente 7,372% 22.01.2021
BG Consulter GmbH, DE <3% 22.01.2021
Yves Sagot, FR 3,382% 20.01.2021
Relief Therapeutics
- positions de vente 9,676% 20.01.2021
BG Consulter GmbH, DE 3,198% 19.01.2021
Relief Therapeutics
- positions de vente 4,151% 19.01.2021
Relief Therapeutics
- positions de vente 0,952% 30.11.2020
Christopher Brown, New York, über 54,8% 12.11.2020
GEM Global Yield LLC SCS, Luxemb.
Relief Therapeutics
- positions de vente 4,371% 12.11.2020
Relief Therapeutics
- positions de vente 24,098% 14.10.2020
Gael Hédou, CH 0,646% 17.09.2020
GEM Global Yield Fund, Luxem. 64,11% 26.08.2020
Relief Therapeutics
- positions de vente 31,49% 26.08.2020
Yves Sagot, FR 4,528% 25.08.2020
Michel Dreano, FR 0,1894% 14.03.2020
Gael Hédou, CH 4,988% 18.03.2020
Michel Dreano, FR 4,78% 17.03.2020
groupe Petrone/Parisi <3% 11.07.2019
groupe Petrone/Parisi 9,54% 14.05.2019
Pierrel S.p.A. 2,98% 07.12.2017
Relief Therapeutics
- positions de vente 163,07% 30.05.2017
Yves Sagot, FR 9,89% 09.11.2017
Gael Hédou, CH 9,95% 06.11.2017
Michel Dreano, FR 9,99% 06.11.2017
Christopher Brown via
GEM Global Yield Fund, Luxem. 163,27% 21.03.2017
Pierrel S.p.A 4,86% 27.03.2017
Relief Therapeutics
- positions de vente 133,66% 21.03.2017
groupe GEM Investments <3% 21.03.2017
Michel Dreano, FR 10,28% 21.03.2017
Yves Sagot, FR 10,27% 21.03.2017
Gael Hédou, CH 10,28% 21.03.2017
groupe Petrone/Parisi 15,65% 14.07.2016
groupe GEM Investments 64,64% 14.07.2016
Relief Therapeutics
- positions de vente 31,5% 14.07.2016
Christopher Brown, New York
- positions d'achat 27% 20.07.2016
Pierrel S.p.A
- positions d'achat 9,68% 20.07.2016
Therametrics
- positions d'achat 3,18% 21.12.2015
- positions de vente 270,88% 21.12.2015
Therametrics
- positions d'achat 3,18% 29.10.2015
- positions de vente 11,72% 29.10.2015
groupe Petrone/Parisi 39,98% 29.10.2015
Therametrics
- positions d'achat 4,96% 05.08.2015
- positions de vente 0,56% 05.08.2015
Therametrics
- positions d'achat 5,88% 03.08.2015
- positions de vente 0,56% 03.08.2015
Therametrics <3% 17.07.2015
Meldegrund: Verfall von Finanzinstrumenten
groupe GEM Investments 182,8% 21.12.2015
Therametrics
- positions de vente 259,16% 21.12.2015
GEM Global Yield Fund, Lux 76,36% 21.12.2015
Pierrel S.p.A., Mailand 32% 21.01.2015
BiopharmaInvest 2,67% 17.09.2014
groupe Petrone/Parisi 35,19% 17.09.2014
groupe Petrone/Parisi 32,22% 15.09.2014
groupe Petrone/Parisi 52,35% 05.09.2014
groupe Petrone/Parisi 40,15% 04.09.2014
groupe Petrone/Parisi 19,89% 06.03.2014
groupe Petrone/Parisi 23,66% 28.02.2014
groupe Petrone/Parisi 13,88% 22.01.2014
groupe Petrone/Parisi 19,98% 16.01.2014
groupe Petrone/Parisi 25,82% 09.12.2013
Gruppe um Prinz von Liechtenstein
(via BiopharmaInvest)
- positions d'achat 4,7% 06.11.2013
- positions de vente 1,58% 06.11.2013
groupe d'actionnaires Fin Posillipo18,26% 13.09.2013
Pierrel S.p.A., Mailand 58,51% 13.09.2013
GEM Global Yield Fund Limited
- positions d'achat 5,47% 13.09.2013
Therametrics
- positions d'achat 1,58% 13.09.2013
- positions de vente 6,53% 13.09.2013
Gruppe um Prinz von Liechtenstein
(via BiopharmaInvest)
- positions d'achat 8,39% 13.09.2013
- positions de vente 1,58% 13.09.2013
Gruppe um Prinz von Liechtenstein
(via BiopharmaInvest)
- positions d'achat 49,21% 01.07.2013
- positions de vente 11,30% 01.07.2013
Gruppe um Prinz von Liechtenstein
(via BiopharmaInvest)
- positions d'achat 52,17% 27.05.2013
- positions de vente 14,81% 27.05.2013
groupe Petrone/Parisi 101,6% 24.05.2013
Pierrel S.p.A., Mailand 325,7% 24.05.2013
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest)
- positions d'achat 54,00% 17.04.2013
- positions de vente 16,63% 17.04.2013
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest)
- positions d'achat 63,08% 30.01.2013
- positions de vente 24,45% 30.01.2013
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest)
- positions d'achat 66,71% 25.01.2013
- positions de vente 28,08% 25.01.2013
Pierrel S.p.A., Mailand
- positions d'achat 440% 24.01.2013
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest)
- positions d'achat 47,71% 11.10.2012
- positions de vente 43,53% 11.10.2012
Therametrics
- positions d'achat 43,53% 17.07.2012
- positions de vente 71,9% 17.07.2012
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest)
- positions d'achat 57,5% 27.06.2012
- positions de vente 43,53% 27.06.2012
Therametrics
- positions d'achat 43,53% 27.06.2012
Imperial Fund, Cayman Island
- positions de vente 0,55% 22.05.2012
Imperial Fund, Cayman Island
- positions de vente 2,2% 16.05.2012
Imperial Fund
- positions d'achat 5,3% 20.09.2011
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest) 57,5% 14.09.2011
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest) 72,93% 21.12.2010
Gruppe um Prinz von Liechtenstein
(via Biopharma Invest) 73,18% 26.08.2009
uh
awp-robot
? Like Cramer admitting to stock manipulation?
and maybe to laugh about too: for the first time ...in oh so very long...SIX is UP at the open!
Maybe now that the shares have been exchanged with GEM at 0.28 VWAP the share price manipulation of selling anywhere between 1 to 5 million shares at the market on the open is history?
BID
Preis Volumen Time
0.315 (1)20000 09:01:28
0.314 (1)19926 09:01:05
0.312 (1)24639 09:00:56
0.311 (2)199865 09:01:47
0.31 (7)201657 09:01:41
0.309 (3)143342 09:01:28
0.308 (3)144154 09:01:28
0.307 (3)240000 09:01:28
0.306 (1)19621 09:01:28
0.305 (3)65579 09:01:36
ASK
09:01:49 (2)37617 0.302
09:01:49 (2)32570 0.301
09:01:48 (5)279033 0.3
09:01:29 (1)20614 0.299
09:01:49 (5)108919 0.298
09:01:28 (6)75973 0.297
09:01:28 (5)279102 0.296
09:00:52 (7)77532 0.295
09:01:28 (2)61758 0.294
09:01:05 (4)99156 0.293
Now there is something to cry about:
GEM is getting 174 million shares at a weighted average of only 0.28SFr in exchange of a draw down facility of 50m$ in cash......
https://www.ser-ag.com/de/resources/notifications-market-participants/significant-shareholders.html#/shareholder-details/TAL3800020
Buying out ACER would cost just as much as this new SSF - 50m$ - and the the swiss markets like it - up to 0.31SFr!
What is really spooky right now is this new Killer variant of COVID19:
Another New Variant: In Oregon, Scientists Find a Virus Variant With a Worrying Mutation
Apoorva Mandavilli
Sat, March 6, 2021, 10:15 AM·4 min read
Coronavirus testing at a Virginia Garcia clinic in Hillsboro, Ore., May 1, 2020. (Ruth Fremson/The New York Times)
Coronavirus testing at a Virginia Garcia clinic in Hillsboro, Ore., May 1, 2020. (Ruth Fremson/The New York Times)
Scientists in Oregon have spotted a homegrown version of a fast-spreading variant of the coronavirus that first surfaced in Britain — but now it's combined with a mutation that may make the variant less susceptible to vaccines.
The researchers have so far found just a single case of this formidable combination, but genetic analysis suggested that the variant had been acquired in the community and did not arise in the patient.
“We didn’t import this from elsewhere in the world — it occurred spontaneously,” said Brian O’Roak, a geneticist at Oregon Health and Science University who led the work. He and his colleagues participate in the Centers for Disease Control and Prevention’s effort to track variants, and they have deposited their results in databases shared by scientists.
Sign up for The Morning newsletter from the New York Times
The variant originally identified in Britain, called B.1.1.7, has been spreading rapidly across the United States, and accounts for at least 2,500 cases in 46 states. This form of the virus is both more contagious and more deadly than the original version, and it is expected to account for most U.S. infections in a few weeks.
The new version that surfaced in Oregon has the same backbone, but also a mutation — E484K, or “Eek” — seen in variants of the virus circulating in South Africa, Brazil and New York City.
Lab studies and clinical trials in South Africa indicate that the Eek mutation renders the current vaccines less effective by blunting the body’s immune response. (The vaccines still work, but the findings are worrying enough that Pfizer-BioNTech and Moderna have begun testing new versions of their vaccines designed to defeat the variant found in South Africa.)
The B.1.1.7 variant with Eek also has emerged in Britain, designated as a “variant of concern” by scientists. But the virus identified in Oregon seems to have evolved independently, O’Roak said.
O’Roak and his colleagues found the variant among coronavirus samples collected by the Oregon State Public Health Lab across the state, including some from an outbreak in a health care setting. Of the 13 test results they analyzed, 10 turned out to be B.1.1.7 alone, and one the combination.
Other experts said the discovery was not surprising, because the Eek mutation has arisen in forms of the virus all over the world. But the mutation’s occurrence in B.1.1.7 is worth watching, they said.
In Britain, this version of the variant accounts for a small number of cases. But by the time the combination evolved there, B.1.1.7 had already spread through the country.
“We’re at the point where B.1.1.7 is just being introduced” into the United States, said Stacia Wyman, an expert in computational genomics at the University of California, Berkeley. “As it evolves, and as it slowly becomes the dominant thing, it could accumulate more mutations.”
Viral mutations may enhance or weaken one another. For example, the variants identified in South Africa and Brazil contain many of the same mutations, including Eek. But the Brazilian version has a mutation, K417N, that is not present in the version from South Africa.
In a study published Thursday in Nature, researchers compared antibody responses to all three variants of concern — the ones identified in Britain, South Africa and Brazil. Consistent with other studies, they found that the variant that pummeled South Africa is most resistant to antibodies produced by the immune system.
But the variant circulating in Brazil was not as resistant, even though it carried the Eek mutation. “If you have the second mutation, you don’t see as bad an effect,” said Michael Diamond, a viral immunologist at Washington University in St. Louis, who led the study.
It’s too early to say whether the variant in Oregon will behave like the ones in South Africa or Brazil. But the idea that other mutations could weaken Eek’s effect is “excellent news,” Wyman said.
Overall, she said, the Oregon finding reinforces the need for people to continue to take precautions, including wearing a mask, until a substantial portion of the population is immunized.
“People need to not freak out but to continue to be vigilant,” she said. “We can’t let down our guard yet while there’s still these more transmissible variants circulating.”
This article originally appeared in The New York Times.
© 2021 The New York Times Company
I understood that but how are we going to get this done?
Obviously Thero and BoD will not move on their own accord as long as they are allowed without protest to spoil themselves senseless with boni they so generously award themselves with while mismanaging OUR(!) company at the same time...
As long as we do not find a way to directly present our concerns to the BoD all we do analyze and theorize here on what improvements could work and what is detrimental to our success sums up in effect to nothing more than "wailing at the rivers of Babylon" and howling at the moon..
All these brilliant minds here with outbursts of creativity and naught comes of it..
It is a crying shame to see this much engaement go to waste which is why we need to get a seat at the table
That is exactly why I suggested earlier that we should organize as an activist shareholder special interest group :
.... a lot of our members on this board here are substantial shareholders...
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial and a higher percentage than many corporate activist raiders clamoring for a board seat represent.
With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again......
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?"
Thx for your thoughtful response Hindukush!
To be clear I was only re-posting something I found on Yahoo this sunday morning which I thought was worthwhile to be considered here. It thoroughly deflated my view that Yahoo posters can only put up memes of rockets and write "to da moon" or "just die".
It is an infuriating situation where so many insights and breakthrough developments are available and hindered by plain old greed and stupidity as well as power plays.
Just like GautamaBuddha taught that the "Root of all Suffering is Ignorance,Aversion and Attachment"
In any case anyone of these big players could do more for VASCEPA to get it's rightful place than Thero and the current BoD ever will which brings me back to my own original idea of the day to establish a shareholder representation as a special interest group representing probably more shares than most "activist stockraiders" bring to the table when they shake up boardrooms :
"
ratna1 Sunday, 03/07/21 04:12:42 AM
Re: HinduKush post# 328194 0
Post #
328460
of 328515
Good Day Hindukush!Glad to see you are still so active with substantive posts giving both meaning and context to an often emotional discussion.
What I do not understand is this:
on this board there are a lot of our members here which are substantial shareholders. I recall a certain plastic surgeon owning in the vicinity of a million shares or so..
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial. With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for at least 4 years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again.
Or is it just a convenient way to express pent up frustration on the abysmal performance of the share price.
I admire the action that you and @Marjac and @BioBill have taken to right the wrongs due to Du being conned with false evidence.
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?"
Thx for the flowers, Changes, but I was only re-posting something I found on Yahoo this sunday morning which I thought was worthwhile to be considered here.It thoroughly deflated my view that Yahoo posters can only put up memes of rocket and write "to da moon" or "just die"
In particular eye opening are the deep roots which this poster named OU3 dug out show that our statistician has a direct channel with the FDA and Biden's administration.
That is encouraging given that Remdesivir is still the only approved therapeutic without proven benefits.
In fact the European Medical Agency is considering to ban it....
Sure, Thx. No idea what Seno could mean. It was just an arbitrary abbrevation that sounded vaguely bad...
Good point, but if you want to shorten my name do it differently. Ratna means juwel... or would you like it if I adress you as Seno?
Maybe you are being rash. To function at all in a pandemic for a state agency that is used to working at snail pace is quite an achievement overall. Also what we perceive as personal insults or conspiracy is mostly inability t perform and/or being undermanned since Trump thinned out public servants in all key agencies so many can hardly perform anymore....
But here is a real glimmer of hope at the end of the tunnel:
I usually do not insult myself by going to the Yahoo board but as it is a cloudy Sunday morning and nobody seems to be here I gave it a try as it seems to have more international posters in various time zones and found this amazing write up today by one OU3:
OU36 hours ago
The day has finally come when we have a glimpse of the hyped CD12 RCT readout by CYDY. The results are mixed at best and the bar is set low enough that Zyesami (Aviptadil) can jump over it as the most effective treatment for severe and critical CV19. While the full data reveal is not out for either company, the highlights from CYDY’s Friday press release indicate that at best, CYDY improved outcomes for what appears to apply to a subset of patients. The press release indicates leronlimab improved release from the hospital by 6 days for critical patients. Re reading the release many times this morning, it appears they sugar coated the facts and leronlimab only had an effect for a subset of 62 of the 384 patients. Unsurprising maneuver given CYDY’s management history. Regardless, the remaining results are observational and do not reveal any effect beyond chance. Further studies will be needed to confirm if any of the observational data can prove out to the FDA. It appears from the release CYDY is now scrambling to make that happen with EIND data. Good luck convincing the FDA with non RCT results. A new study will be required and with it they will need additional funding.
As for Zyesami, this week will be crucial, as the pressure is on to see the 60 day results, but interestingly it’s not their only shot to be discovered. The iSpy inhaled study is still in the works and given that Covid is not going away anytime soon according to nearly all the knowledgeable medical advice, I like Zyesami’s chances!
While CYDY may be left for dead trying to fund future trials with an inept executive team and shady financier who is now under serious SEC investigations, Zyesami’s inclusion in the iSpy trial by NIH and plenty of cash by the mothership Relief means Zyesami is very much still in the game.
The most promising fact is that the preliminary results released two weeks ago on Zyesami indicated a medical effect of the drug after 28 days on a subset of HFNC patients. However, there is more to be revealed for Zyesami IV. In fact, my prediction is that Javitt will reveal moderately significant results at 60 days. Why? Because there is a slow down in the progression of the disease due to SOC and this fact masks the results at 28 days. However, my hunch is that after 60 days the differences will be revealed. Add in the the radiographic data (CT Scans) of the lungs, and we will have the ability at the very least to excite the FDA and investors.
The fact remains that this is the first trial ever undertaken with this drug to address CV19 and admittedly Javitt underdosed patients with Zyesami, but Javitt was smart enough to make sure our endpoints were reset and there is enough scientific data included in the trial to detect a “medical signal” (using his words). CYDY did the opposite by not resetting endpoints and firing Dr. Bruce Patterson at IncellDx which excluded his brilliant cellular marker data which would have helped CYDY’s case of detecting a “medical signal” due to the drug. Investors in Zyesami already see signs of this benefit in the EIND results with the compelling lung scan data. While not a primary endpoint for the study, the FDA cares about these medically relevant facts and its unfortunate for CYDY investors that they accepted Nader Pourhassen’s lies to cover up why they kicked Bruce off the team and hurt shareholders!
Lastly, the impact of this drug on Long Haulers (SARS-CoV-2 - PASC) pulmonary issues is the holy grail few are realizing. A vast percentage of long haulers are suffering longterm lung damage and this MAY BE THE ONLY TREATMENT on planet earth that can help them in the FDA pipeline.
? Leronlimab - no
? Other MABs - no
? Arthritis drugs - no
? Synairgen - no,
? EXO-CD24 - no,
? Zyesami - Yes it’s possibly effective for post infection pulmonary recovery.
To recap. I’m disappointed in Leronlimab. It failed it’s primary endpoint which was mortality. If it met it, the press release would have screamed it... it did not. Furthermore, it failed every other secondary unless one subgroup was broken out (62 critical patient in the CYDY study), however this population size is not large enough to convince the FDA regardless of significance.
Zyesami was in a similar boat 2 weeks ago but they have another shot with the upcoming 60 day analysis and the incredible good fortune that FDA changed the requirements for all drug companies targeting CV19.
Add in that NeuroRx has direct ties to Lavin the leading FDA consultant in this industry with direct personal ties to former FDA commissioner David Bessler- now on Biden CV Taskforce, be assured Zyesami is very much still in the game and CYDY is on the outside far behind these connected companies... yet it’s share price puts it at 4x the Market Cap of RLFTF...
I like my chances with RLFTF and BRPAW, BRPR, BRPA family of investments.
Go #RLFTF #BRPA
OU
I usually do not insult myself by going to the Yahoo board but as it is a cloudy Sunday morning and nobody seems to be here I gave it a try as it seems to have more international posters in various time zones and found this truly amazing idea, which borders on a stroke of genius.
IT would solve all our problems in one swift move:
ELUTEA13 hours ago
I saw a post on this message board showing how Lovaza , not generic Vascepa, continues to be the largest competitor to Vascepa due to the power of the massive marketing muscle of GSK. I couldn't agree more, and is why I've wondered why GSK hasn't bought AMRN. As a healthcare worker in the pharmaceutical industry there is ABSOLUTELY no more powerful way to switch from a previous product to the latest product than when the exact same company comes in with their exact same sales reps and details the docs to convert to the newer product...its just a natural evolution of the process vs trying to completely change a mindset. Imagine being able to capture all current Vascepa scripts, highly effectively convert the Brand and Lovaza scripts to Vascepa, and if needed also provide a generic version in those areas where generic V is present, ALL UNDER 1 ROOF. Has to be under consideration. The combination of current V scripts and Lovaza scripts, branded and generic, is already WELL OVER $1 billion. Kick in the international growth of V coming in 2021 and beyond and its a multi-billion dollar seller. 2nd best bet is a statin maker, ie AstraZeneca, Pfizer or Merck, to come out with a branded combination product. Buy strong at these lows in the $4-6 range...one of the 2 above ideas should come to fruition within 3 years.
I am all for legal challenges and a class action is a civil suit but given all the evidence is this not a a case of criminal negligences on part of the doctors prescribing Lovaza?
Aren't they insured for such omissions of duty?
Why should they be protected if they fail their patients?
In european law (which is codified and still based on the roman codex in contrast to anglo saxon case law in which every new verdict is actually changing the law) there is a legal term "Omission to Help" or "Failure to give First Aid" which is a criminal offence.
Unbelievably telling admission in court hat you found, Duke!
Now is there a legal way to punish them for such graft?
I mean not in the patent arena but in terms of criminal justice as it constitutes a willful intent to risk lives or at least induce physical suffering and financial and emotional losses for financial gains!
Our legal experts o board here may be able to tell if this would go as far as voluntary manslaughter.
100% correct, Hindukush! I also read this piece and was infuriated fór all it's selfserving aggrandizement. But is there any recourse or legal mechanism to have her excluded from any court proceedings re. patents due to such a blatant self incriminating admission of bias and political partisan ship?
How will you and how should we as a group of activist shareholders get it to management if they are so hardheaded?
Shoulda-woulda-coulda has brought us here...
Just plain bitching hasn't changed a thing yet..
Perfectly valid point! How could you and we as a group of share- and stakeholders bring this about?
Good Day Hindukush!Glad to see you are still so active with substantive posts giving both meaning and context to an often emotional discussion.
What I do not understand is this:
on this board there are a lot of our members here which are substantial shareholders. I recall a certain plastic surgeon owning in the vicinity of a million shares or so..
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial. With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for at least 4 years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again.
Or is it just a convenient way to express pent up frustration on the abysmal performance of the share price.
I admire the action that you and @Marjac and @BioBill have taken to right the wrongs due to Du being conned with false evidence.
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?
Good Day Hindukush!Glad to see you are still so active with substantive posts giving both meaning and context to an often emotional discussion.
What I do not understand is this:
on this board there are a lot of our members here which are substantial shareholders. I recall a certain plastic surgeon owning in the vicinity of a million shares or so..
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial. With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for at least 4 years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again.
Or is it just a convenient way to express pent up frustration on the abysmal performance of the share price.
I admire the action that you and @Marjac and @BioBill have taken to right the wrongs due to Du being conned with false evidence.
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?
Actually this is old news from Jan.21st:
https://advita-lifescience.com/wp-content/uploads/20210120_PR_Relief_AdVita_EN.pdf
https://advita-lifescience.com/
And ADVITA is semi-private as it was founded, funded and 100% owned up to now by the teaching hospital of the University of Freiburg which is BTW the same university that first christened the new found continents to the West as AMERIGA in the 15hundreds
Here's one for you too:
Does VIP function as modulator in regions of the brain associated with anxiety and depression
https://www.nature.com/articles/s41598-020-80873-2
nature scientific reports articles Published: 14 January 2021
Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females
Rozalyn A. Simon, Nawroz Barazanji, Michael P. Jones, Olga Bednarska, Adriane Icenhour, Maria Engström, J. Paul Hamilton, Åsa V. Keita & Susanna Walter
Scientific Reports
volume 11, Article number: 1406 (2021) Cite this article
Abstract
Vasoactive intestinal polypeptide (VIP) is a neuroendocrine peptide distributed throughout the human body, including the CNS, where it is particularly abundant in brain regions associated with anxiety and depression. Based on earlier studies indicating that peripheral VIP may cross through the blood–brain barrier, we hypothesized plasma VIP levels to be associated with symptoms of anxiety and depression, as well as brain volume and resting-state functional connectivity in the amygdala, hippocampus, parahippocampus, and orbitofrontal cortex.
Plasma VIP concentrations and anxiety/depression symptoms were measured in 37 healthy females. Functional and structural magnetic resonance imaging were used to evaluate functional connectivity and brain volume respectively, and their associations with VIP concentrations within brain regions associated with anxiety and depression. Negative correlations were found between VIP levels and symptoms of anxiety (r?=?- 0.44, p?=?0.002) and depression (r?=?- 0.50, p?=?0.001). Functional connectivity demonstrated significant VIP-dependent positive associations between the amygdala seed region with both the right parahippocampus (t(33)?=?3.1, pFDR?=?0.02) and right lateral orbitofrontal cortex (OFC; t(33)?=?2.9, pFDR?=?0.02). Moreover, VIP concentrations were significantly, positively correlated with brain volume in the left amygdala (r?=?0.28, p?=?0.007) and left lateral OFC (r?=?0.29, p?=?0.004).
The present findings highlight a potential role for VIP in the neurobiology of affective symptoms.
I believe this was the post I had in mind! Thank you! Unfortunately on re-reading the stúdies linked it does not adress wether it could substitute Immunoglobulin injections and Plasmapheresis for MS and peripheral neuropathic disorders
ChangesIV,this is great stuff and this one I have not seen before.
I was specifically wondering wether it would be possible that VIP could substitute immunoglobulin injections in cases of MS or severe neuropathy with it's resulting damage done to myelin sheathing..
You need to look at the company press releases for details:
https://www.relieftherapeutics.com/company
The Company's name is AdVita and it is a spin off from the pulmonary department of the University Hospital with the declared purpose to find therapeutic solutions for rare lung diseases:
https://advita-lifescience.com/
https://advita-lifescience.com/wp-content/uploads/20210120_PR_Relief_AdVita_EN.pdf
Don't have the time, really... HAPPY TRAILS
Uncle, where art thou?
I have an interesting update on re-infections for your DD tabella
https://www.denverpost.com/2021/03/01/colorado-coronavirus-second-infection/amp/
p.s.:
lost the link for your great effort. Would you kindly re-post it?
Thx, but if this was not from the good doctor himself I would discard this as a short FUD or a weak attempt to justify delays in their discussion with the FDA or BARDA etc...
Seems like a detour..
Where exactly is that interview source? Do you have a link and if it is a lengthy interview at what time is the relevant discussion?
As far as inhaled VIP is concerned it has been in use here at the university teaching hospital for years for Sarcoidosis and Pneumonia..
RLF is in fact buying out the company that is producing it here locally by share-exchange.
Also BACHEM has produced VIP for 2 decades now...
It does not make sense that he is saying this in particular since the SEC filing about the merger with BRPA is spelling out the complete opposite about production capabilities!
You might want to ask Belfort directly. He is most knowledgeable about these matters
Hi Peg, as I read your disclosure earlier I am aware of the enormous pressure of suffering you are under. However where does this worry about manufacturing capabilities come from? Any foundation in reality or is it more emotional which is not meant to put it down as I deeply appreciate the underestimated value of nurturing emotions in any healing process?
Did I miss any development that your worries are based on?
BACHEM e.g., who is producing he inhaled version has been producing it for a decade with a lot of experience and the ability to scale up instantly and has hired more and more experts in the production of hormones recently.
Yes, Elk, I am sure RLF100 would certainly mitigate if not reverses degenerative processes caused by COVID however my question to Changes was about Neuropathy, MS and a other demyelinating diseases
Hi Changes, since VIP seems to undo damage to the myelin sheathing and regerneate nerve cell growth (which is basically impossible in conventional thinking..) I wonder wether it could substitute the need for the extremely costly Plasmapheresis treatment for autoimmune diseases?
I remember you posted about IgA once before but cannot find it...
https://en.wikipedia.org/wiki/Plasmapheresis
https://www.healthline.com/health/plasmapheresis
Good Day Changes! Don't know if you came across this study on cell death in liver cancer yet:
Cancer Sci. 2019 Jan;110(1):235-244. doi: 10.1111/cas.13861. Epub 2018 Dec 4.
Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway
https://pubmed.ncbi.nlm.nih.gov/30390393/
With the plethora of data you have been providing you are both an inspiration and a valuable resource for information to disseminate to colleagues.
Unfortunately I have not been able to keep track of your gumshoeing efforts with your numerous posts as I just don't have the time to go through tem one by one... which is why I would like to suggest (time permitting) that you put your findings into an table much like Uncle Gee Gee once sorted all his DD last year
(BTW where did he drift off to?)
In this way your valuable contribution would not get lost in the flood of posts her on this board. Especially not if you - or a moderator - would sticky it at the top of the page
Thank you again for your efforts
Best Rgards
Ratna
Rose, I don't get it: Thero is obligated by law to inform stockholders of any buyout offer. He just cannot deal in a dark room.
Thanks Abe! I am afraid you are right even so a BO should be at least 3 x times current shareprice...
Buy Outs happen all the time and VASCEPA is definitely a trophy asset
What I don't get is this:
the shareholders are the ones deciding on any A&M activity and need to be notified by the company any time an offer is made..
But her on this board there has been an atmosphere for years that it is the ultimate decision of Thero alone.
What's wrong in this picture?